RECRUITING

Tempus CRC Surveillance Study: a CtDNA Biomarker Profiling Study of Patients with CRC Using NGS Assays

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

Official Title

Tempus CRC Surveillance Study: a Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays

Quick Facts

Study Start:2022-06-21
Study Completion:2027-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05234177

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Known or suspected colorectal adenocarcinoma (Stage I to IV disease)
  2. * Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.
  3. * 18 years old or older
  4. * Willing and able to provide informed consent
  5. * Willing to have additional blood samples collected during routine surveillance visits
  1. * Not willing to have additional blood samples collected
  2. * Pathology that is not consistent with colorectal adenocarcinoma

Contacts and Locations

Study Contact

CRC Surveillance Study
CONTACT
(833) 514-4187
gemini-crc@tempus.com

Principal Investigator

Kristiyana Kaneva, MD, MS
PRINCIPAL_INVESTIGATOR
Tempus AI, Inc.

Study Locations (Sites)

Mercy Clinic Oncology - Fort Smith
Fort Smith, Arkansas, 72903
United States
MemorialCare
Fountain Valley, California, 92708
United States
The Center for Cancer and Blood Disorders
Bethesda, Maryland, 20817
United States
Mercy Clinic Oncology and Hematology - Joplin
Joplin, Missouri, 64804
United States
Washington University School of Medicine
Saint Louis, Missouri, 63110
United States
Mercy Clinic Oncology and Hematology - Sindelar Cancer Center
Saint Louis, Missouri, 63128
United States
Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center
Saint Louis, Missouri, 63141
United States
Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center
Springfield, Missouri, 65804
United States
Nebraska Cancer Specialists
Omaha, Nebraska, 68130
United States
Southeastern Medical Oncology Center
Goldsboro, North Carolina, 27543
United States
Aultman Hospital
Canton, Ohio, 44710
United States
TriHealth Cancer Institute
Cincinnati, Ohio, 45220
United States
Ohio State University
Columbus, Ohio, 43210
United States
OhioHealth Research Institute
Columbus, Ohio, 43214
United States
Toledo Clinic Cancer Center
Toledo, Ohio, 43623
United States
Mercy Clinic Oncology and Hematology - Coletta
Oklahoma City, Oklahoma, 73120
United States
Cancer Care Associates of York
York, Pennsylvania, 17403
United States
Utah Cancer Specialists
Salt Lake City, Utah, 84124
United States
University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington, 98109
United States
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
United States

Collaborators and Investigators

Sponsor: Tempus AI

  • Kristiyana Kaneva, MD, MS, PRINCIPAL_INVESTIGATOR, Tempus AI, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-21
Study Completion Date2027-02

Study Record Updates

Study Start Date2022-06-21
Study Completion Date2027-02

Terms related to this study

Keywords Provided by Researchers

  • Cancer
  • Oncology
  • Observational
  • Genomic Profiling
  • Precision medicine
  • CRC
  • Colorectal Cancer
  • NGS
  • Biomarkers

Additional Relevant MeSH Terms

  • Colorectal Cancer